Skip to main content

Illumina's Q1 Revenues Rise 148 Percent as R&D Nearly Doubles; Solexa Buy Widens Loss

NEW YORK (GenomeWeb News) — Illumina today said first-quarter revenues increased 148 percent as R&D spending nearly doubled and the company posted a $300 million net loss affected by acquisition-related charges.
 
Total receipts for the three months ended March 31 increased to $72.2 million from $29.1 million year over year.
 
Product revenues nearly tripled, rising to $61.2 million from $21.3 million, while service and other revenue more than doubled to $10.8 million from $5.2 million year over year.
 
R&D spending almost doubled to $16 million from $8.2 million in the year-ago period.
 
Illumina said net loss swelled to $298 million from $104,000 in the year-ago period. The $600-million acquisition of Solexa in late January, which included a $303 million charge, had the greatest impact on the loss, Illumina said.
  
Illumina said it had around $326 million in cash, cash equivalents, and short-term investments as of March 31.
 
The company said it expects 2007 revenue to be between $305 million and $315 million.
 
Second-quarter revenues are expected to be between $74 million and $78 million.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.